Complexation of Docetaxel in Cyclodextrin Derivates With Different Methods and Characterization of Inclusion Complexes
Abstract
Keywords
References
- 1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures. Atlanta, GA, USA: The American Cancer Society 2007.
- 2. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006; 17(5):735-749.
- 3. Varan C, Bilensoy E. Development of hydroxypropyl β-cyclodextrin:Polycaprolactone nanoparticles for the controlled delivery of docetaxel to solid tumors. J Inclus Phenom Macroc Chem 2014; 80(1-2):9-15.
- 4. Immordino ML, Brusa P, Arpicco S, et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 2003; 91(3):417-429.
- 5. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001; 19(2):125-141.
- 6. Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009; 13(1):49-59.
- 7. Yavuz B. Siklodekstrin Kompleksi Oluşturarak, Ekzemestan'ın Çözünmesinin ve İn Vitro Geçirgenliğinin Arttırılması. Yüksek Lisans Tezi, Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü, Ankara 2009; ss 2.
- 8. Terwogt JM, Nuijen B, Ten Bokkel Huinink WW, et al. Alternative formulations of paclitaxel. Cancer Treat Rev 1997; 23(2):87-95.
Details
Primary Language
Turkish
Subjects
-
Journal Section
-
Authors
Sedat Ünal
This is me
Çiğdem Yücel
This is me
Serdar Tort
This is me
Merve Ç.tekeli
This is me
Yeşim Aktaş
This is me
Erem Bilensoy
This is me
Publication Date
July 1, 2017
Submission Date
July 1, 2017
Acceptance Date
-
Published in Issue
Year 2017 Volume: 26 Number: 2